Related Experiment Video
Updated: Aug 20, 2025

Development and Functionalization of Electrolyte-Gated Graphene Field-Effect Transistor for Biomarker Detection
Published on: February 1, 2022
Ultrasensitive dopamine detection with graphene aptasensor multitransistor arrays
Mafalda Abrantes1,2,3,4, Diana Rodrigues2,3, Telma Domingues1
1International Iberian Nanotechnology Laboratory, 4715-330, Braga, Portugal.
This study presents a graphene multitransistor array (gMTA) sensor for ultrasensitive dopamine detection. The novel sensor achieves a 1 aM limit-of-detection, enabling advancements in brain disorder diagnostics and research.
Area of Science:
- Neuroscience
- Materials Science
- Biotechnology
Background:
- Accurate detection of neurotransmitters like dopamine is crucial for understanding brain disorders.
- Existing sensors often struggle with sensitivity and reliability in complex biological samples.
- Developing ultrasensitive and robust neurotransmitter detection platforms is a key challenge.
Purpose of the Study:
- To develop a highly sensitive and reproducible platform for detecting dopamine at physiological levels.
- To demonstrate the utility of graphene multitransistor arrays (gMTAs) functionalized with DNA aptamers for neurotransmitter sensing.
- To overcome limitations of current sensors in detecting low analyte concentrations in complex biological matrices.
Main Methods:
- Fabrication of wafer-level graphene multitransistor arrays (gMTAs) on small chips.
- Functionalization of gMTAs with DNA aptamers for selective dopamine binding.
- Utilizing a multiple sensor array configuration for robust, simultaneous replicate measurements.
- Testing sensor performance in various buffers, complex biological samples, and CSF from a Parkinson's disease mouse model.
Main Results:
- Achieved an ultra-low limit-of-detection (LOD) of 1 aM (10^-18 M) for dopamine.
- Demonstrated a wide dynamic detection range from 1 aM to 100 µM (10 orders of magnitude).
- Exhibited high sensitivity (22 mV/decade) and reproducibility in complex biological samples, including brain homogenates and mouse CSF.
- Successfully detected minimal dopamine concentration changes in small-volume CSF samples from a Parkinson's disease model.
Conclusions:
- The developed gMTA platform offers robust and ultrasensitive dopamine detection.
- This technology overcomes sensitivity limitations in complex biological samples, paving the way for improved diagnostics.
- The platform holds significant potential for real-world research, pre-clinical studies, and clinical diagnosis of brain disorders.
More Related Videos
09:28Engineering Molecular Recognition with Bio-mimetic Polymers on Single Walled Carbon Nanotubes
Published on: January 10, 2017
11:18Manufacturing of a Nafion-coated, Reduced Graphene Oxide/Polyaniline Chemiresistive Sensor to Monitor pH in Real-time During Microbial Fermentation
Published on: January 7, 2019